Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RXGOLF who wrote (14405)	2/6/1998 10:49:00 PM
From: Henry Niman	Respond to of 32384

1998 should be better. Here's what Dow Jones said about LGND's press release: Ligand Pharma Results -4: To Begin Mktg Strategy This Year Ligand Pharmaceuticals Inc. (LGND) said it plans to file three New Drug Applications with the U.S. Food and Drug Administration in 1998 or early 1999. The company said during 1997 it completed its largest strategic alliance with Eli Lilly, completed two trials with positive results for Panretin Gel in Kaposi's sarcoma, and had positive interim Phase III results for Targretin in cutaneous T-cell lymphoma. The company said these accomplishments during the year made it "financially strong and well positioned" to begin its commercialization strategy this year, and it expects to become profitable in 1999. Ligand Pharmaceuticals is a drug company.

To: RXGOLF who wrote (14405)	2/6/1998 10:55:00 PM
From: Henry Niman	Respond to of 32384

RXGOLF, Biotechs disappointed in 1997 and really didn't do their share. I expect the sector to do better this year and LGND to do EXTREMELY well. LGND could get approval recs on 3 NDAs this year, quite an impressive number compared with 39 new drugs approved last year, most of which was done by the big boys.

To: RXGOLF who wrote (14405)	2/7/1998 10:08:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Ligand will also be covered well in Monday's IBD. They weren't included in the NASDAQ summary, but a table of their impressive financials will appear under the "Up" earnings reports and the table includes a 130% increase in sales. Yesterday's 201% increase in volume captured the #70 slot in the NASDAQ Greatest % Rise in Volume table. Moreover, LGND was #7 in the 15 Most % Up In Price table (and of course they were the only Biotech). Biotechs as a group also did well. The 2.1% gain for Medical-Biomed/Genetics group was tied for the #2 slot among the 197 industry groups. It looks like the Biotech Boom may have started 1-2 months later than usual.